Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Revenue (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Revenue for 3 consecutive years, with $15.0 million as the latest value for Q1 2025.

  • Quarterly Revenue changed N/A to $15.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $15.0 million for FY2025, N/A changed from the prior year.
  • Revenue for Q1 2025 was $15.0 million at Centessa Pharmaceuticals, up from -$2.6 million in the prior quarter.
  • The five-year high for Revenue was $15.0 million in Q1 2025, with the low at -$2.6 million in Q4 2023.
  • Average Revenue over 3 years is -$242666.7, with a median of -$2.2 million recorded in 2022.
  • Peak annual rise in Revenue hit 16.66% in 2023, while the deepest fall reached 56.33% in 2023.
  • Over 3 years, Revenue stood at -$2.2 million in 2022, then decreased by 16.66% to -$2.6 million in 2023, then soared by 683.66% to $15.0 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $15.0 million, -$2.6 million, and -$2.5 million for Q1 2025, Q4 2023, and Q3 2023 respectively.